ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Express Scripts to add Zepbound to National Preferred Formulary
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Decision on EU marketing authorisation expected for momelotinib by early 2024
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Subscribe To Our Newsletter & Stay Updated